共 279 条
[1]
Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424
[2]
Ferlay J(2019)NCCN guidelines insights: ovarian cancer, version 1.2019 J Natl Compr Canc Netw 17 896-909
[3]
Soerjomataram I(2018)Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer N Engl J Med 379 2495-2505
[4]
Siegel RL(2019)Niraparib in patients with newly diagnosed advanced ovarian cancer N Engl J Med 381 2391-2402
[5]
Torre LA(1996)Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer N Engl J Med 335 1950-1955
[6]
Jemal A(2001)Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group J Clin Oncol 19 1001-1007
[7]
Armstrong DK(2006)Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 34-43
[8]
Alvarez RD(2019)Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG oncology/gynecologic oncology group study J Clin Oncol 37 1380-1390
[9]
Bakkum-Gamez JN(2006)Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a gynecologic oncology group study Gynecol Oncol 100 27-32
[10]
Barroilhet L(1983)Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection Cancer Res 43 1426-1431